Clinical trials: DRD
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 103 sites in Australia, Czechia and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT07095452
- Testing
- Etentamig, Lenalidomide, Daratumumab
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 680 people
- Sponsor
- AbbVie
Multiple Myeloma, Myeloma Multiple
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
- Trial name
- NCT04782687
- Testing
- Selinexor, Dexamethasone Oral, Daratumumab
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- US Oncology Research
Multiple Myeloma
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of daratumumab, lenalidomide and dexamethasone (DRd) to that of modified bortezomib, lenalidomide and dexamethasone (VRd-lite), in terms of progression-free survival…
- Trial name
- NCT06497738
- Where
- 6 sites in China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Myeloma
REal World MAIA UK OutcomEs
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated…
- Trial name
- REMAKE (NCT07532473)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Dystonia, Dystonia; Idiopathic
Dystonia Genotype-Phenotype Correlation
The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to…
- Conditions
- Dystonia, Dystonia; Idiopathic, Dystonia, Primary, Dystonia, Secondary
- Trial name
- NCT03428009
- Testing
- Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with…
- Trial name
- NCT02252172
- Testing
- Daratumumab IV, Lenalidomide, Dexamethasone
- Where
- 206 sites in United States, Australia and 11 more
- Volunteers
- 737 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating…
- Trial name
- NCT06042725
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Parkinson Disease, Multiple System Atrophy
Research of Biomarkers in Parkinson Disease
The main goal of the GENEPARK consortium is to employ innovative haemogenomic approaches to determine gene expression profiles specific for genetic and idiopathic Parkinson's disease (PD) patients.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Huntington Disease
- Trial name
- Genepark (NCT00465790)
- Where
- 5 sites in Croatia, France and 2 more
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Myeloma
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in…
- Trial name
- NCT02076009
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 145 sites in United States, Australia and 16 more
- Volunteers
- 569 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Newly Diagnosed Multiple Myeloma
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
- Trial name
- DREAMM-10 (NCT06679101)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 181 sites in United States, Argentina and 22 more
- Volunteers
- 520 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Newly Diagnosed
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
MYLENE is a prospective, multicenter, NIS to evaluate the patient and HCP satisfaction of sc and iv application of daratumumab in routine clinical practice in Germany.
- Conditions
- Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction
- Trial name
- MYLENE (NCT05284591)
- Testing
- Daratumumab
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- iOMEDICO AG
Parkinson, Dystonia
Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
Hereditary Parkinson and dystonia syndromes are rare, as are people who carry the predisposition for Parkinson or dystonia but do not have symptoms.
- Conditions
- Parkinson, Dystonia, DYT3, DYT5
- Trial name
- SensoMo-PD (NCT05713721)
- Testing
- Transcranial magnetic stimulation (TMS), Video-based clinical examination, 24 hours drug withdrawal of dopaminergic medication
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Multiple Myeloma
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab…
- Trial name
- MajesTEC-7 (NCT05552222)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Where
- 270 sites in United States, Australia and 23 more
- Volunteers
- 1,590 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, DRD
A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
The goal of this study is to observe and evaluate the incidence of infection in newly diagnosed, non-transplanted multiple myeloma patients receiving prophylactic treatment with sulpegfilgrastim (a pegylated recombinant human…
- Conditions
- Multiple Myeloma, DRD, Sulpegfilgrastim, Neutropenia
- Trial name
- NCT07018271
- Testing
- sulpegfilgrastim
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
The purpose of this study is to evaluate the safety of daratumumab when combined with lenalidomide and dexamethasone in Japanese participants with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy…
- Trial name
- NCT02918331
- Testing
- Daratumumab (16 mg/kg), Lenalidomide, Dexamethasone
- Where
- 5 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.